Medical consequences of acromegaly: What are the effects of biochemical control?

被引:27
作者
Colao, Annamaria [1 ]
Auriemma, Renata S. [1 ]
Pivonello, Rosario [1 ]
Galdiero, Mariano [1 ]
Lombardi, Gaetano [1 ]
机构
[1] Univ Naples Federico II, Dept Mol & Clin Endocrinol & Oncol, I-80131 Naples, Italy
关键词
acromegaly; GH; IGF-I; biochemical control; cardiovascular; joints; respiratory diseases; neoplasms; dyslipidemia; diabetes;
D O I
10.1007/s11154-007-9062-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This chapter discusses the effects of biochemical control of acromegaly on cardiovascular diseases, metabolic complications, respiratory abnormalities, malignancies and bone alterations. Acromegaly is associated with increased morbidity and mortality for cardiovascular and respiratory complications, whereas neoplasms seem to be a minor cause of increased risk of death. Other associated diseases are osteoarthritis, carpal tunnel syndrome, fatigue, visual abnormalities and reproductive disorders. Acromegaly results in premature death because of prolonged elevation of GH an IGF-I levels, and a strong biochemical control improves well-being and restores life expectancy to normal. The main goals of medical treatment of acromegaly include normalization of biochemical markers of disease activity, improvement in signs and symptoms of the disease, removal or reduction of tumor mass and preservation of pituitary function.
引用
收藏
页码:21 / 31
页数:11
相关论文
共 95 条
[1]   LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy [J].
Arosio, M ;
Sartore, G ;
Rossi, CM ;
Casati, G ;
Faglia, G ;
Manzato, E .
ATHEROSCLEROSIS, 2000, 151 (02) :551-557
[2]   Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients [J].
Baldelli, R ;
Ferretti, E ;
Jaffrain-Rea, ML ;
Iacobellis, G ;
Minniti, G ;
Caracciolo, B ;
Moroni, C ;
Cassone, R ;
Gulino, A ;
Tamburrano, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (02) :527-532
[3]   AN ASSOCIATION BETWEEN ACROMEGALY AND THYROID-CARCINOMA [J].
BALKANY, C ;
CUSHING, GW .
THYROID, 1995, 5 (01) :47-50
[4]   Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant [J].
Barkan, AL ;
Burman, P ;
Clemmons, DR ;
Drake, WM ;
Gagel, RF ;
Harris, PE ;
Trainer, PJ ;
van der Lely, AJ ;
Vance, ML .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (10) :5684-5691
[5]   Prevalence of diabetes in acromegaly and Cushing's disease [J].
Biering, H ;
Knappe, G ;
Gerl, H ;
Lochs, H .
ACTA MEDICA AUSTRIACA, 2000, 27 (01) :27-31
[6]   Peroxisome proliferator activated receptor γ expression is reduced in the colonic mucosa of acromegalic patients. [J].
Bogazzi, F ;
Ultimieri, F ;
Raggi, F ;
Costa, A ;
Gasperi, M ;
Cecconi, E ;
Mosca, F ;
Bartalena, L ;
Martino, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (05) :2403-2406
[7]   Early vascular alterations in acromegaly [J].
Brevetti, G ;
Marzullo, P ;
Silvestro, A ;
Pivonello, R ;
Oliva, G ;
Di Somma, C ;
Lombardi, G ;
Colao, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (07) :3174-3179
[8]  
BURT RW, 1988, GASTROENTEROL CLIN N, V17, P657
[9]  
Castro GFM, 2000, CLIN ENDOCRINOL, V53, P313
[10]  
Cats A, 1996, CANCER RES, V56, P523